Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $209.5 million.

  • Dr Reddys Laboratories' Cash & Equivalents changed N/A to $209.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $209.5 million, marking a year-over-year change of. This contributed to the annual value of $172.0 million for FY2025, which is 10235.29% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Cash & Equivalents of $209.5 million as of Q4 2025.
  • Dr Reddys Laboratories' 5-year Cash & Equivalents high stood at $81662.2 billion for Q2 2022, and its period low was $69.9 million during Q3 2023.
  • Over the past 5 years, Dr Reddys Laboratories' median Cash & Equivalents value was $168.2 million (recorded in 2025), while the average stood at $4536.9 billion.
  • Per our database at Business Quant, Dr Reddys Laboratories' Cash & Equivalents skyrocketed by 7371969266.14% in 2022 and then tumbled by 9999.99% in 2023.
  • Dr Reddys Laboratories' Cash & Equivalents (Quarter) stood at $293.3 million in 2021, then plummeted by 74.01% to $76.2 million in 2022, then decreased by 8.3% to $69.9 million in 2023, then increased by 21.38% to $84.9 million in 2024, then soared by 146.9% to $209.5 million in 2025.
  • Its Cash & Equivalents stands at $209.5 million for Q4 2025, versus $167.3 million for Q3 2025 and $170.5 million for Q2 2025.